Current understanding of hepatic and intestinal OATP-mediated drug–drug interactions

Role of Organic Anion-Transporting Polypeptides for Cellular Mesalazine (5-Aminosalicylic Acid) Uptake

(2011) J. Konig et al.   DRUG METABOLISM AND DISPOSITION

Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations

(2011) A. M. Filppula et al.   DRUG METABOLISM AND DISPOSITION

Effect of the CYP2C8 Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide

(2011) D. Tomalik-Scharte et al.   DRUG METABOLISM AND DISPOSITION

Clinical Importance of OATP1B1 and OATP1B3 in Drug­Drug Interactions

(2011) Yoshihisa Shitara   Drug Metabolism and Pharmacokinetics

Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro

(2011) Johanna Weiss et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Evaluation of possible drug-drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP)

(2011) Alexander Huppertz et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells

(2010) Anja Zahno et al.   BIOCHEMICAL PHARMACOLOGY

Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren

(2010) Tuija Tapaninen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast

(2010) T Karonen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine

(2010) R Spence et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design

(2010) M L Reitman et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Hepatic Uptake of the Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA: Role of Human Organic Anion Transporters

(2010) M. Leonhardt et al.   DRUG METABOLISM AND DISPOSITION

Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren

(2010) Tuija Tapaninen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin

(2010) Lloyd R. Whitfield et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Hepatocellular Carcinoma: Hepatocyte-selective Enhancement at Gadoxetic Acid–enhanced MR Imaging—Correlation with Expression of Sinusoidal and Canalicular Transporters and Bile Accumulation

(2010) Takahiro Tsuboyama et al.   RADIOLOGY

The effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatinin vivo

(2010) E. Bergman et al.   XENOBIOTICA

Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells

(2009) Satoru Seki et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

No significant effect ofABCB1haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin

(2009) Jenni E. Keskitalo et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins

(2009) Michael J. Knauer et al.   CIRCULATION RESEARCH

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism

(2009) Yi-Jing He et al.   CLINICA CHIMICA ACTA

Drug Uptake Systems in Liver and Kidney: A Historic Perspective

(2009) B Hagenbuch   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe

(2009) J. T. Backman et al.   DRUG METABOLISM AND DISPOSITION

Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for Atorvastatin

(2009) J. Niessen et al.   DRUG METABOLISM AND DISPOSITION

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

(2009) Ichiro Ieiri et al.   Expert Opinion on Drug Metabolism & Toxicology

Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan

(2009) Duncan B. Richards et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Hepatic OATP1B Transporters and Nuclear Receptors PXR and CAR: Interplay, Regulation of Drug Disposition Genes, and Single Nucleotide Polymorphisms

(2009) Henriette E. Meyer zu Schwabedissen et al.   MOLECULAR PHARMACEUTICS

Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response

(2009) Edward B. Mougey et al.   Pharmacogenetics and Genomics

Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer

(2008) W. Lee et al.   CANCER RESEARCH

Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer

(2008) A. Hamada et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren

(2008) Sujata Vaidyanathan et al.   CLINICAL PHARMACOKINETICS

Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism

(2008) A Kalliokoski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite

(2008) HX Zheng et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: A randomized, single-blind, placebo-controlled, crossover study

(2008) Wei Zhang et al.   CLINICAL THERAPEUTICS

Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1

(2008) I. Bachmakov et al.   DIABETES

Methotrexate Pharmacokinetics in Transgenic Mice with Liver-Specific Expression of Human Organic Anion-Transporting Polypeptide 1B1 (SLCO1B1)

(2008) E. van de Steeg et al.   DRUG METABOLISM AND DISPOSITION

The solute carrier (SLC) complement of the human genome: Phylogenetic classification reveals four major families

(2008) Robert Fredriksson et al.   FEBS LETTERS

Different Effects ofSLCO1B1Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide

(2008) Annikka Kalliokoski et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P-Glycoprotein in the Disposition of Aliskiren

(2008) Sujata Vaidyanathan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin

(2008) H. Zaher et al.   MOLECULAR PHARMACOLOGY

No significant effect ofSLCO1B1polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone

(2007) Annikka Kalliokoski et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY